• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Varadan Anand

    1/30/23 4:05:42 PM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PULM alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Varadan Anand

    (Last) (First) (Middle)
    C/O PULMATRIX, INC., 99 HAYDEN AVE

    (Street)
    LEXINGTON MA 02421

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Pulmatrix, Inc. [ PULM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/26/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $3.99 01/26/2023 A 1,700 (1) 01/26/2033 Common Stock 1,700 $0 1,700 D
    Explanation of Responses:
    1. The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 26, 2023, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan.
    /s/ Anand Varadan 01/30/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PULM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PULM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PULM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Pulmatrix with a new price target

      HC Wainwright & Co. reiterated coverage of Pulmatrix with a rating of Buy and set a new price target of $5.00 from $10.00 previously

      4/13/21 6:23:02 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    Leadership Updates

    Live Leadership Updates

    See more

    $PULM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PULM
    Financials

    Live finance-specific insights

    See more
    • Pulmatrix appoints Director Anand Varadan

      LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Anand Varadan to its Board of Directors, effective July 26, 2021. Mr. Varadan brings expertise in commercialization and successful product launches. In addition, Mark Iwicki stepped down from his role on the Board of Directors effective July 23, 2021. "We are delighted to welcome Anand to

      7/27/21 10:00:00 AM ET
      $PULM
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • SEC Form 4 filed by Batycky Richard P.

      4 - Pulmatrix, Inc. (0001574235) (Issuer)

      1/30/23 4:05:40 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Varadan Anand

      4 - Pulmatrix, Inc. (0001574235) (Issuer)

      1/30/23 4:05:42 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Cabell Christopher

      4 - Pulmatrix, Inc. (0001574235) (Issuer)

      1/30/23 4:05:43 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

      PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in cash and cash equivalents at the end of 2022 providing cash runway into Q2 2024 LEXINGTON, Mass., March 30, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2022 and provided a corporate update on its development programs.

      3/30/23 9:05:00 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

      Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025 As part of proposed merger, Pulmatrix intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology FRAMINGHAM, Mass., March 21, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced fourth quarter and year-end financi

      3/21/25 8:05:00 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain

      SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cullgen Inc. ("Cullgen"), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE™ platform to discover and advance therapeutics for the treatment of cancer and other diseases, today announced that it has begun dosing in human subjects to evaluate its potential first-in-class, oral, pan-TRK protein degrader for the treatment of pain. CG001419 is a highly active small molecule designed to selectively degrade both mutant and wild-type TRK proteins and is being developed to be a new, non-opioid, non-NSAID analgesic therapy as part of a new class of pain signal inhibitors that have the

      1/22/25 8:00:00 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pulmatrix and Cullgen Announce Proposed Merger

      Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of cancer and one for the treatment of acute and chronic pain Combined company expected to have approximately $65 million of cash and cash equivalents at close to provide funding through multiple clinical milestones and expected runway through 2026 As part of merger agreement, Pulmatrix intends to divest its assets including its acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology Cullgen and Pulmatrix will host an informational webcast about the propose

      11/13/24 9:00:00 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    SEC Filings

    See more
    • SEC Form 424B3 filed by Pulmatrix Inc.

      424B3 - Pulmatrix, Inc. (0001574235) (Filer)

      5/9/25 4:55:25 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-4/A filed by Pulmatrix Inc.

      S-4/A - Pulmatrix, Inc. (0001574235) (Filer)

      5/6/25 9:51:14 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-4/A filed by Pulmatrix Inc.

      S-4/A - Pulmatrix, Inc. (0001574235) (Filer)

      4/17/25 8:39:23 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pulmatrix Inc. (Amendment)

      SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)

      1/2/24 9:42:57 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pulmatrix Inc. (Amendment)

      SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)

      2/8/23 6:08:04 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pulmatrix Inc. (Amendment)

      SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)

      1/10/23 11:21:19 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care